We are live on ! Find out more
NBIX icon

Neurocrine Biosciences
NBIX

121 hedge funds and large institutions have $1.12B invested in Neurocrine Biosciences in 2014 Q1 according to their latest regulatory filings, with 31 funds opening new positions, 54 increasing their positions, 23 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

135% more repeat investments, than reductions

Existing positions increased: 54 | Existing positions reduced: 23

105% more capital invested

Capital invested by funds: $547M → $1.12B (+$576M)

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

48% more call options, than puts

Call options by funds: $10.4M | Put options by funds: $7.04M

19% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 26

3% more funds holding

Funds holding: 117 → 121 (+4)

Holders
121
Holders Change
+4
Holders Change %
+3.42%
% of All Funds
3.49%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.06%
New
31
Increased
54
Reduced
23
Closed
26
Calls
$10.4M
Puts
$7.04M
Net Calls
+$3.37M
Net Calls Change
-$1.83M

Top Buyers

Rank Fund Capital Flow
1
O
OrbiMed
New York
+$48.2M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$20.5M
3
RCM
RA Capital Management
Massachusetts
+$20M
4
BA
BlackRock Advisors
Delaware
+$17.4M
5
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$16.2M

Top Sellers

Rank Fund Capital Flow
1
Invesco
Invesco
Georgia
-$13.9M
2
State Street
State Street
Massachusetts
-$8.63M
3
Millennium Management
Millennium Management
New York
-$7.76M
4
VM
VHCP Management
New York
-$6.69M
5
Deutsche Bank
Deutsche Bank
Germany
-$5.47M
Name Holding Trade Value Shares
Change 		Change in
Stake
AllianceBernstein
51
AllianceBernstein
Tennessee
$2.03M -$119K -6,964 -5%
ProShare Advisors
52
ProShare Advisors
Maryland
$2.02M +$1.55M +90,732 +263%
BlackRock
53
BlackRock
New York
$1.89M +$1.97M +115,012 +5,259%
TA
54
Teachers Advisors
New York
$1.58M +$39.9K +2,330 +2%
UOC
55
UBS O'Connor
Illinois
$1.56M +$1.65M +96,671 New
LCM
56
Laurion Capital Management
New York
$1.54M +$1.64M +95,900 New
California Public Employees Retirement System
57
California Public Employees Retirement System
California
$1.46M +$83.8K +4,900 +5%
Prudential Financial
58
Prudential Financial
New Jersey
$1.43M +$6.84K +400 +0.5%
AIG
59
American International Group
New York
$1.41M +$739K +43,183 +98%
EAM
60
Eventide Asset Management
Massachusetts
$1.41M +$835K +48,800 +127%
Swiss National Bank
61
Swiss National Bank
Switzerland
$1.35M +$419K +24,500 +41%
HCMT
62
Highland Capital Management (Texas)
Texas
$1.29M +$1.37M +80,000 New
DM
63
Deerfield Management
New York
$1.26M +$1.33M +77,994 New
Wells Fargo
64
Wells Fargo
California
$1.15M +$1.22M +71,208 +70,503%
SB
65
Suntrust Banks
Georgia
$1.11M +$1.18M +68,757 New
RhumbLine Advisers
66
RhumbLine Advisers
Massachusetts
$1.08M -$54.7K -3,200 -5%
DBG
67
De Burlo Group
Massachusetts
$1.06M +$416K +24,300 +59%
GPCM
68
Granite Point Capital Management
Massachusetts
$1.04M +$168K +9,800 +18%
American Century Companies
69
American Century Companies
Missouri
$1.01M +$1.07M +62,760 New
State Board of Administration of Florida Retirement System
70
State Board of Administration of Florida Retirement System
Florida
$993K – – –
MLICM
71
Metropolitan Life Insurance Company (MetLife)
New York
$930K +$25.7K +1,501 +3%
NIMI
72
Natixis Investment Managers International
France
$876K +$931K +54,413 New
NFA
73
Nationwide Fund Advisors
Ohio
$871K +$44.6K +2,606 +5%
JMPWA
74
JP Morgan Private Wealth Advisors
California
$837K +$889K +52,000 New
3NC
75
300 North Capital
California
$824K +$45.7K +2,669 +6%
1 2
3
4 5

NBIX Hedge Fund Activity: Q1 2014 in Review

121 of the 3,463 institutional investors tracked by Wall St. Rank reported a position in Neurocrine Biosciences (NBIX) for Q1 2014, worth a combined $1.12B — up 105% from $547M a quarter earlier.

Buyers outnumbered sellers: 31 funds opened new NBIX positions and 26 closed out — a net gain of 5 holders — while 54 added to existing stakes and 23 trimmed.

The largest buyer was OrbiMed, adding an estimated $48.2M. The largest seller was Invesco, cutting an estimated $13.9M.

  • 121 institutional investors held Neurocrine Biosciences (NBIX) as of Q1 2014, up from 117 in Q4 2013.
  • Funds reported $1.12B of Neurocrine Biosciences stock for Q1 2014, up 105% quarter-over-quarter.
  • 31 funds opened new Neurocrine Biosciences positions in Q1 2014 and 26 closed out, a net change of +5 holders.
  • The largest Neurocrine Biosciences buyer in Q1 2014 was OrbiMed, an estimated $48.2M added.
  • The largest Neurocrine Biosciences seller in Q1 2014 was Invesco, an estimated $13.9M sold.

Based on aggregated 13F filings for Q1 2014.